Table 2.
Medications used in this study.
| Medications | Total (n) | Group C | Group S |
|---|---|---|---|
| SGLT2i (n = 28) | |||
| Empagliflozin | 12 | – | 12 |
| Ipragliflozin | 5 | – | 5 |
| Luseogliflozin | 5 | – | 5 |
| Canagliflozin | 3 | – | 3 |
| Tofogliflozin | 3 | – | 3 |
| ARB (n = 26) | |||
| Telmisartan | 9 | 3 | 6 |
| Olmesartan | 7 | 4 | 3 |
| Candesartan | 5 | 3 | 2 |
| Valsartan | 3 | 1 | 2 |
| Irbesartan | 2 | 2 | 0 |
| ACEI (n = 2) | |||
| Enarapril | 2 | 1 | 1 |
SGLT2i sodium-glucose cotransporter 2 inhibitor, ARB angiotensin II type1 receptor blocker, ACEI angiotensin converting enzyme inhibitor.